MiPS (Mi Prostate Score Urine test)
- Aliases
-
- MPS
- MiPS (Mi Prostate Score Urine test)
- Description
- The MiPS assay is a multiplex analysis of T2-ERG gene fusion, PCA3, and serum PSA (KLK3). It is commercially available through the University of Michigan MLabs. The MiPS assay tests for the presence of two prostate cancer biomarkers: a piece of RNA made from the PCA3 gene, found to be overactive in 95 percent of all prostate cancers, and another RNA marker that is found only when TMPRSS2 and ERG abnormally fuse. TMPRSS2:ERG, or T2-ERG, is a strong indicator of prostate cancer.
Attributes
- QA State
- Curated
- Type
- Genomic
- HGNC Name
- Certifications
- QA State for Prostate
- Curated
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
- Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
- Beyond PSA: the next generation of prostate cancer biomarkers.
- Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
- Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.
- From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.
- Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
- Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
- Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
- Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.